CD33 and acute myeloid leukemia: Since CD33 and CD123 markers are expressed on the majority of AML cells, they have been used to generate innovative tools such as CD33/CD3 (AMG330) [22, 23] or CD3/WT1-HLA-A*0201 [24] BiTEs or chimeric antigen receptors (CAR) targeting CD123 epitope [25–27].